2018
DOI: 10.1016/j.jaci.2017.11.034
|View full text |Cite
|
Sign up to set email alerts
|

Endogenous and exogenous sex steroid hormones in asthma and allergy in females: A systematic review and meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
72
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 56 publications
(74 citation statements)
references
References 75 publications
2
72
0
Order By: Relevance
“…Human glucagon-like peptide 1 (GLP-1) is an incretin hormone that was initially described in the 1980s as a proglucagon cleavage product, produced by intestinal cells in response to food intake [1]. Its main actions are stimulation of insulin secretion, suppression of glucagon production, delay in gastric emptying, induction of satiety in the central nervous system, and reduction of postprandial triglyceride and free fatty acid concentrations [2]. Given its main hypoglycemic properties, GLP-1 has become an important therapeutic target in type 2 diabetes.…”
Section: Fundingmentioning
confidence: 99%
See 4 more Smart Citations
“…Human glucagon-like peptide 1 (GLP-1) is an incretin hormone that was initially described in the 1980s as a proglucagon cleavage product, produced by intestinal cells in response to food intake [1]. Its main actions are stimulation of insulin secretion, suppression of glucagon production, delay in gastric emptying, induction of satiety in the central nervous system, and reduction of postprandial triglyceride and free fatty acid concentrations [2]. Given its main hypoglycemic properties, GLP-1 has become an important therapeutic target in type 2 diabetes.…”
Section: Fundingmentioning
confidence: 99%
“…Given its main hypoglycemic properties, GLP-1 has become an important therapeutic target in type 2 diabetes. However, a major limitation of its use was its very short half-life [2]. This was overcome by the development of synthetic GLP-1 receptor agonists, which can be divided into short-acting GLP-1 receptor agonists (exenatide and lixisenatide) and long-acting GLP-1 receptor agonists (longacting release [LAR] exenatide, liraglutide, albiglutide, and dulaglutide).…”
Section: Fundingmentioning
confidence: 99%
See 3 more Smart Citations